All In MedTech

Device Trial Radar · NCT05746286

Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia

Continuous, Real-time, Remote Monitoring of Vital Signs With Telehealth to Prevent Readmissions for Dysglycemia: Discharge Remote Monitoring System (DIREMOS)

Last checked: Nov 19, 2026Latest source record: Nov 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Feb 1, 2023

Primary completion

Nov 29, 2023

Study completion Jun 24, 2024

Sponsor

Lead sponsor
DexCom, Inc.Public (DXCM)
Sponsor type
Industry
First posted
Feb 27, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated device
Yes
Who can join
All sexes, from 21 years, up to 110 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients who have experienced dysglycemia in hospital (either from diabetes, post-solid organ transplantation, medication titration, or other causes) may struggle to manage their blood glucose when discharged home. This may lead to ER visits or readmissions that could have been prevented if glucose variations were detected before reaching extremes, and the variations were contextualized with other vital sign parameters. Remote monitoring via Dexcom G6 and Current Health (vital signs) used concomitantly after discharged for the purpose of remote monitoring will be evaluated with respect to ER visits and readmissions while considering the impact and usability of the potential integrated system on the healthcare staff.

Conditions

  • Dysglycemia

Interventions

  • Dexcom G6 CGMDevice

    Once discharged, the patients will be monitored by the endocrine team via routine "dashboard rounds" during working hours (8AM-5PM). Outside of dashboard rounds, management will be by exception, based on platform alarms directed to the endocrinology service.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reduce amount of ER readmission in first 30 days after dischargeTime frame: 30 days
  2. Pilot study satisfaction surveyTime frame: 30 days or less per patient

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mount Sinai School of Medicine

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.